Tumor Biology

, Volume 35, Issue 1, pp 595–601 | Cite as

Clinical characteristics and prognostic factors of prostate cancer with liver metastases

  • HaiTao Wang
  • BaoGuo Li
  • PengYu Zhang
  • YanHong Yao
  • JiWu Chang
Research Article


Liver metastasis from prostate cancer is uncommon and remains poorly understood. We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29 %. Eight (29.63 %) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37 %) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group (p = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan–Meier curves and logrank tests for univariate analysis.


Liver metastases Prostate cancer Predictive factors Survival 


The study was supported by NSFC (81071787) and Tianjin Municipal Science and Technology Commission (08JCYBJC10300).

Conflicts of interest



  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21:1323–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Guerin S, Hill C. Cancer epidemiology in France in 2010, comparison with the USA. Bull Cancer. 2010;97:47–54.PubMedGoogle Scholar
  4. 4.
    Na YQ, Sun G, Ye ZQ, Sun YH, Sun ZY. Guideline of Chinese urological disease diagnosis and treatment. Beijing: People’s Health Publishing House; 2009.Google Scholar
  5. 5.
    Zheng RS, Zhang SW, Wu LY, Li GL, Ping Z, Hao J. Report of incidence and mortality in China Cancer Registries, 2008. China Cancer. 2012;21:1–12.Google Scholar
  6. 6.
    Whitmore Jr WF. Natural history and staging of prostate cancer. Urol Clin North Am. 1984;11:205–20.PubMedGoogle Scholar
  7. 7.
    Pouessel D, Gallet B, Bibeau F, Avancès C, Iborra F, Sénesse P, et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int. 2007;99:807–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, et al. Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). J Clin Oncol. 2012;30(suppl; abstr 4655).Google Scholar
  9. 9.
    Marech I, Vacca A, Sivestris N, Gnoni A, Lorusso V (2013) Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: a case report. Onco Lett 5(6):1877-80 doi: 10.3892/ol.2013.1275.Google Scholar
  10. 10.
    Caffo O, Gernone A, Ortega C, Sava T, Cartenì G, Facchini G, et al. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol. 2012;107:191–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Shao Q, Ouyang J, Fan Y, Xie J, Zhou J, Wu J, et al. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration. Cancer Lett. 2012;315:170–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer. 2000;88:2590–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12:109–17.PubMedCrossRefGoogle Scholar
  16. 16.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943–7.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of Interventional Oncology, Tianjin Cancer Hospital and InstituteTianjin Medical UniversityTianjinChina
  2. 2.Research Group of Evidence-based Clinical OncologyTianjinChina
  3. 3.Tianjin Key Laboratory of Cancer Prevention and TherapyTianjinChina
  4. 4.Tianjin Institute of Urological SurgeryTianjin Medical UniversityTianjinChina

Personalised recommendations